All In Vivo Testing articles
-
NewsNew culture system yields billions of rare dendritic cells for preclinical research
A new 23-day bone marrow culture protocol produces over 1.5 billion conventional type 1 dendritic cells from a single mouse, offering researchers a consistent, high-purity supply of a cell type critical to tumour immunology and vaccine development.
-
NewsMulti-lab study challenges reproducibility of psilocybin behavioural findings
A landmark multi-institution collaboration has found no reproducible lasting behavioural changes in mice 24 hours after a single psilocybin dose, raising important questions about research reproducibility in psychedelic drug discovery.
-
NewsBispecific antibody targets regulatory T cells to enhance tumour immunity
A bispecific antibody targeting CCR8 and CD3 has demonstrated the ability to deplete immunosuppressive regulatory T cells and slow tumour growth across multiple cancer models.
-
NewsDual-therapy approach targets TNBC energy supply in preclinical study
A combination of a CD276-targeting antibody-drug conjugate and mitochondria-disrupting gene therapy has demonstrated anti-tumour activity in preclinical models of metastatic triple-negative breast cancer.
-
ArticleWhat will it take to trust human-relevant models in drug discovery?
Could organ-on-a-chip technology help identify drug failures before clinical trials? Jim Corbett of Emulate discusses the evidence needed to make human-relevant models reliable tools in drug discovery.
-
NewsMLY2 and MLY8 compounds show promise as ulcerative colitis treatment candidates
Two experimental compounds derived from a phase II metabolite have demonstrated improved anti-inflammatory activity in preclinical models of ulcerative colitis.
-
NewsResearchers solve 30-year mystery of key inflammatory enzyme gene
A gene responsible for producing a critical enzyme in inflammatory signalling has been identified after more than 30 years, with findings suggesting the pathway acts as both an immune alarm and a cellular shield with implications for cancer, IBD and asthma.
-
NewsTazbentetol shows retinal neuroprotection potential in diabetic mouse model
Experimental synaptic restoration compound tazbentetol has demonstrated neuroprotective effects in the retinas of diabetic mice, offering a potential new therapeutic avenue for diabetic retinal neuropathy ahead of detectable vascular damage.
-
NewsVPS34 inhibition boosts GD2 visibility to enhance neuroblastoma immunotherapy
Penn State researchers have shown that inhibiting the protein VPS34 increases GD2 display on neuroblastoma cell surfaces, making tumours more visible to anti-GD2 antibodies and improving outcomes in preclinical combination studies.
-
NewsCMA restoration may clear senescent cells in ageing tissues
Researchers at Albert Einstein College of Medicine have identified a cellular recycling pathway whose age-related decline allows senescent ‘zombie’ cells to evade immune clearance.
-
NewsMenin inhibitor KO-7246 shows β-cell regeneration in preclinical diabetes models
New preclinical data suggests that menin inhibitor KO-7246 can regenerate functional pancreatic β-cells and sustain improvements in blood glucose control across both Type 1 and Type 2 diabetes models.
-
NewsIn vivo CAR T review charts path to off-the-shelf cellular therapy
A review from researchers at Naval Medical University and Shanghai Jiao Tong University examines how engineering CAR T cells directly inside the body could cut manufacturing complexity and expand patient access to cellular immunotherapy.
-
NewsExperimental drug reverses paralysis and vision loss in MS mice
A novel inflammasome inhibitor derived from HIV antivirals has reversed established neurological deficits in a preclinical MS model, raising hopes for a restorative approach to a disease where current therapies focus primarily on relapse prevention.
-
NewsVaccine adjuvant AS01 shown to induce trained immunity in monocytes
A preclinical study published in Myeloid Cells reports that AS01, a vaccine adjuvant system, can induce trained immunity in human monocytes and reduce tumour growth in selected mouse cancer models.
-
NewsBCG and immunotherapy combination cuts tuberculosis relapse risk
Combining the BCG vaccine with a B-cell-targeting immunotherapy significantly reduced tuberculosis relapse rates in preclinical models.
-
NewsLiver cancer organoids used to screen 1,600 potential treatments
Researchers at the University of Basel have screened more than 1,600 compounds using a biobank of 35 hepatocellular carcinoma organoids, identifying drug combinations that show selective anti-tumour activity across biologically diverse liver cancers.
-
NewsWhy researchers are targeting Nav1.7 in the search for longer-lasting pain relief
Humanised antibodies targeting the voltage-gated sodium channel Nav1.7 have demonstrated prolonged suppression of neuropathic pain in a rat model.
-
NewsExperimental RNA drug reverses scleroderma signs in preclinical study
An experimental synthetic non-coding RNA drug has reversed signs of systemic sclerosis in patient-derived immune cells and mouse models, with researchers now preparing an IND application to the FDA.
-
NewsWhy cancer drug CADD522 could offer a new route to treating osteoporosis
A compound originally designed to block a cancer-associated protein has demonstrated unexpected benefits for bone health and metabolism in post-menopausal mice, suggesting a potential new mechanism for osteoporosis drug discovery.
-
NewsGLP-1 drug semaglutide extends lifespan and slows ageing in older mice
A new NIH-funded study suggests the GLP-1 receptor agonist semaglutide may slow biological ageing and extend lifespan in older mice, raising the prospect that GLP-1 drugs could one day be developed as broad longevity-enhancing interventions.